<DOC>
	<DOCNO>NCT02024477</DOCNO>
	<brief_summary>Type 2 diabetes national epidemic . Diabetes undesirable effect blood vessel may contribute heart disease . Endothelial Progenitor Cells ( EPCs ) find blood . Research show improve survival special blood cell may decrease harmful effect diabetes blood vessel reduce reverse heart disease . Saxagliptin FDA ( Food Drug Administration ) approve prescription medicine use along diet exercise lower blood sugar people Type 2 diabetes . It class diabetes medication call DPP-4 inhibitor . DPP-4 inhibitor show increase EPCs patient Type 2 diabetes . Hypothesis : We believe poor viability function EPCs early diabetes ultimately affect repair regeneration endothelium prompt intervention use saxagliptin another oral hypoglycemic agent , Metformin , may reduce reverse cardiovascular risk improve EPC survival function beyond adequate glucose metabolism control .</brief_summary>
	<brief_title>Effect Saxagliptin EPCs Cellular Biomarker Evaluating Endothelial Dysfunction Early T2DM Patients</brief_title>
	<detailed_description>Type 2 diabetes national epidemic 1,2 significant macro microvascular complications3 . Insulin resistance prediabetes early late diabetes associate endothelial dysfunction4 . A study indicate EPCs act suitable bio-marker 5-7 monitoring cardiovascular morbidity . In proposal suggest EPCs CD34 positive cell act suitable cellular biomarker estimate follow endothelial dysfunction early type 2 diabetes patient . EPCs use regenerative tool ischemic myocardium diabetic wound heal 8-13 . Endothelial dysfunction associate inflammation may consequence excess super-oxide presence set diabetes pro-oxidative stress condition cause EPC dysfunction senescence14 . Therefore monitor EPC number , function gene expression may serve useful cellular bio-marker cardiovascular complication early type 2 diabetes . Though lifestyle modification propose main stay prevention treatment early type 2 diabetes , 2 , 15-19 several new therapy diabetes developed recent years2 . Incretins incretin mimetics appear hold promise . Oral DPP-4 inhibitor show increase EPCs patient type 2 diabetes 20 reportedly via SDF-1 alpha up-regulation . Interestingly , up-regulation SDF-1 alpha vascular endothelial growth factor ( VEGF ) , chemotactic factor increase mobilization recruitment EPCs face acute ischemic injury repair regeneration.21-24 . Several study show positive effect incretins ( Glucagon like peptide , GLP-1 ) incretin receptor agonist ( GLP-1 receptor agonist ) cardiovascular risk factor type 2 diabetes patients20,25 even patient chronic heart failure leave ventricular dysfunction diabetes26,27 . DPP-4 Inhibitors may cardio-protective effect , increase bio-availability endogenous GLP-1 . They improve blood flow nitric oxide production endothelium28 , 29 . These unique property demonstrate oral diabetes medication 28 . The mechanism underlying effect may mediate increase nitric oxide bioavailability completely know . It possible Saxagliptin , member DPP-4 inhibitor group drug may able improve number function CD34+ endothelial progenitor cell up-regulating chemotactic agent SDF1 alpha ( DPP-4 degrade SDF-1 ) receptor CXCR47 , 20 , 21 , 30 , 31 . Poor viability function EPCs early diabetes may ultimately affect repair regeneration endothelium prompt intervention may reduce reverse cardiovascular risk improve EPC survival function beyond adequate glucose metabolism control . Therefore would like explore effect saxagliptin addition lifestyle intervention , number function gene expression EPC impact endothelial dysfunction type 2 diabetes .</detailed_description>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Saxagliptin</mesh_term>
	<criteria>Inclusion Criteria 1 . Adults age 4070 year . 2 . Diagnosis type 2 diabetes within previous 8 year use criterion American Diabetes Association 3 . Currently treat hypoglycemic agent stable dose ( &gt; 3 month ) metformin ( ≥1.0 ≤2 gram daily ) . 4 . HbA1C 6 9 % ( inclusive ) 5 . BMI 25 39.9 kg/m2 ( inclusive ) 1 . Contraindications moderate exercise 2 . Implanted device ( e.g. , pacemaker ) may interact Tanita scale 3 . Previous coronary cerebrovascular event within 6 month screen active clinically significant coronary and/or peripheral vascular disease . 4 . Low hematocrit &lt; 28 Units 5 . Preexisting liver disease and/or ALT AST &gt; 2.5X 's UNL 6 . Kidney disease ( serum creatinine level ≥1.5 mg/dL men , ≥1.4 mg/dL woman , Creatinine Clearance ≤50 mL/min ) 7 . History pancreatitis , cancer ( except basal cell carcinoma ) 8 . Statin use start ( dose change ) last 3 month . 9 . Use oral injectable antidiabetic medication Metformin 10 . Use form consistentlong term steroid medication ( oral , inhaled inject nasal ) within last 3 month 11 . Systolic BP &gt; 140 mmHg diastolic BP &gt; 90 mmHg 12 . Active wound recent surgery within 3 month . 13 . Inflammatory disease , current use antiinflammatory drug 14. triglyceride &gt; 400 mg/dL 15. untreated hyper/hypothyroidism Additionally , patient active smoker , patient pregnant , nurse woman , post menopausal woman hormone replacement therapy exclude . Patients low dose oral contraceptive allow participate formulation contain less amount estrogen .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>endothelial cell</keyword>
	<keyword>cellular biomarker</keyword>
	<keyword>endothelial dysfunction</keyword>
</DOC>